cytuvax

Novel Vaccination Technology

CyTuVax has developed an intelligent vaccination platform technology for the treatment of cancer. The main benefit is a powerful adjuvant composed of depot-bound immune response modifiers. These depot-bound immune response modifiers in precisely defined dose windows are a crucial innovation: they do not merely act as a simple adjuvant, but also instruct the tissue at the injection site to form a highly organized and active immunological nodule: “the vaccine machine”. Within this nodule, tumor antigens and immune response modifiers are delivered to the cells of the immune system in a long-lasting and controlled manner. This allows full control of the specificity, direction, and strength of the resulting immune response.

Vaccine at work

Fig. 1 The CyTuVax Vaccine at Work: depot-bound cytokines (green) and tumor cells/fragments (red).

Proof of Concept

Animal tests.

The proof-of-concept of the CyTuVax vaccine technology has been shown in numerous animal experiments with a wide variety of antigens tumors. The vaccine has been tested with very positive results with murine tumors: melanoma, kidney, colon and lymphoma.

First in human.

For a first proof of concept in humans, CyTuVax will combine its adjuvant with autologous tumor cells to develop a vaccination treatment for pancreatic tumors.

CyTuVax’ Mission Statement

Our mission is to help patients fight cancer by developing effective vaccines that help the patient’s immune system to eliminate tumor cells.

Adjuvant Technology Licensing